Clinical Research Directory
Browse clinical research sites, groups, and studies.
Impact of Probiotics on Neuropathy Induced by Adjuvant Chemotherapy in Patients With Colon Cancer.
Sponsor: Centre Francois Baclesse
Summary
The pbjective of this study is to assess the impact of a multi-strain bacteria probiotic OXXYSLAB® on the reduction of oxaliplatin-induced peripheral neuropathy in patients with stage III colon cancer receiving FOLFOX or XELOX regimen in adjuvant treatment, assessed using the oxaliplatin-specific scale of Levi.
Official title: Impact of Probiotic Supplementation on Neuropathy Induced by Adjuvant Chemotherapy in Patients With Colon Cancer: a Phase III Randomized Study
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
130
Start Date
2026-10-01
Completion Date
2036-04-01
Last Updated
2026-07-30
Healthy Volunteers
No
Conditions
Interventions
PROBIOTIC SUPPLEMENTATION BY OXXYSLAB®
PROBIOTIC treatment (OXXYSLAB®) starts 1 week before first administration of chemotherapy (XELOX or FOLFOX) and be continued until 1 week after end of the last cycle of chemotherapy. PROBIOTIC treatment (OXXYSLAB®) is administered orally , in 1 daily dose.
PLACEBO supplementation
PLACEBO supplementation starts 1 week before first administration of chemotherapy (XELOX or FOLFOX) and be continued until 1 week after end of the last cycle of chemotherapy. PROBIOTIC treatment (OXXYSLAB®) is administered orally , in 1 daily dose.
Locations (7)
Centre François Baclesse
Caen, Centre François Baclesse, France
Ch Aunay-Bayeux
Bayeux, France
CHU
Caen, France
Centre Oscar Lambret
Lille, France
CHU
Lille, France
CHU
Rouen, France
CH
Saint-Lô, France